◆英語タイトル：Anti-obesity Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
The global anti-obesity drugs market was valued at about USD 1,690 million in 2020 and is expected to reach USD 4,250 million in 2026, by registering a CAGR of 15% over the forecast period.
In the current COVID-19 situation it was also observed that obesity has increased exponentially. As per an article published by the European Journal of Nutrition in December 2020, the rate of obesity has increased in the world. The major reason being a change in lifestyle and a decrease in exercise practice in the population owing to the avoidance of gyming and yoga classes by the majority of the population due to the current social distancing protocols and. This increase in the obesity population is expected to increase the demand for anti-obesity drugs in near future.
According to a report published by Our World In Data in 2017, 13% of adults in the world are obese and 39% of all adults in the world are overweight. Each one-in-five children and adolescents, globally, are overweight. Incidences of obesity is increasing fiercely over the past decades and it is often described as a global endemic, especially in the developed countries where lifestyle associated disorders such as anxiety, stress, smoking, drinking are more prevalent.
Owing to the increase in the obesity population worldwide, the key players in the market are also undergoing product development and seeking market approvals. For instance, in 2018, a Danish pharma company Novo Nordisk entered into a strategic partnership with Evotec AG to discover and develop drug molecules to treat several metabolic disorders including obesity, diabetes, and other associated disorders. Later on In December 2020, Novo Nordisk submitted a marketing authorization application to the European Medicines Agency (EMA), seeking approval for a once-weekly semaglutide for weight management.
In addition, research on several potential drug molecules that target both obesity and type 2 diabetes mellitus has become a key trend in the anti-obesity market players. The increasing epidemic of obesity and type 2 diabetes is encouraging researchers and vendors in the market to research drugs that can counter both obesity and type 2 diabetes. Hence, the increasing obesity population along with an increase in unhealthy eating habits and a sedentary lifestyle is expected to drive market growth over the forecast period.
However, the availability of alternative therapies and the potential side-effects caused by the anti-obesity drugs are expected to restraint market growth.
Key Market Trends
Prescription Drugs Segment is Expected to Exhibit a Better Growth Rate over the Forecast Period
By Drug Type, the Prescription Drug segment is expected to hold a significant market share. In the current COVID-19 scenario, various companies are exploring the new class of medicines that helps people lose weight and control diabetes as a potential in fighting pandemic disease. As COVID-19 has seen severe consequences in the obese population. In September 2020, Novo Nordisk A/S, that they are performing research on GLP-1 drug used for obesity in COVID-19 patients. These research and development activities in the future are expected to propel the demand for prescription drugs. Moreover, the rising intake of junk foods/fast foods is resulting in declining health among the population, worldwide. and leading to an increase in the prevalence of obesity, especially in some developed parts of the world. For instance, in the United States, from 1999–2000 to 2017–2018, the prevalence of obesity increased from 30.5% to 42.4%, and the prevalence of severe obesity increased from 4.7% to 9.2%, as per the 2018 report by the Centers for Disease Control and Prevention.
In June 2020, China Medical System Holdings signed a USD 400 million-plus agreement for Chinese commercialization rights to US biotech Gelesis Inc.’s prescription obesity management product Plenty. All these development by the players coupled with increasing awareness of prescription medicine is anticipated to boost the growth of the prescription drug segment.
North America is Expected to Dominate the Market over the Forecast Period
North America is expected to dominate the global anti-obesity drugs market, The primary factors driving the growth of the market studied are an increase in the obese population and high healthcare spending.
In September 2020, The Centers for Disease Control and Prevention (CDC) notified that adult obesity prevalence is increasing and racial and ethnic disparities persist owing to the current circumstances of work from home, less physical activities, financial and other stress among the adult population. The CDC stated that obesity remains high, and currently, twelve states have an adult obesity prevalence at or above 35 % including Alabama, Arkansas, Indiana, Kansas, Kentucky, Louisiana, Michigan, Mississippi, Oklahoma, South Carolina, Tennessee, and West Virginia which is much high as compared to 2018 where 9 states reported 35% obese population.
Also, according to the finding of CDC in 2017-18, the age-adjusted prevalence of obesity in adults was 42.4%, and there were no significant differences between men and women among all adults or by age group. Also, as per the data published by Organisation for EconomicCo-operation and Development, in Canada 59.1% of the population aged 15 years or more was obese whereas in Mexico, 75.2% of the population aged 15 years or more was obese 2017- 2018.
The high obesity rate has always attracted the key players to make developments in the region. For instance, in 2020, Kintai Therapeutics, a United States headquartered company, announced that they are working across therapeutic areas and is beginning IND-enabling studies for its first potential therapeutic for the treatment of obesity. The first drug candidate is KTX-0200, which has demonstrated sustained weight loss and improvements in other markers of health in animal models. The launch of these pipeline products along with the increasing geographic footprints of the player is expected to propel market growth in this region.
The presence of major market players, such as GlaxoSmithKline PLC, Novo Nordisk AS, Pfizer Inc., F Hoffmann-La Roche AG, and Bayer AG, is increasing the overall competitive rivalry of the market. The key players are focused on inorganic growth strategies organizations such as collaborating with successful personality, initiative, or programs at the national levels, which promote their product. Therefore, these are recognized earlier than other brands in the market studied. With the high prevalence rate of the disease, the intensity of competitive rivalry is moderate to high.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Obesity and Related Chronic Diseases
4.2.2 Growing Unhealthy and Sedentary Lifestyle
4.3 Market Restraints
4.3.1 Availability of Alternative Treatment Options
4.3.2 Side Effect of Drugs
4.4 Industry Attractiveness – Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Mechanism of Action
5.1.1 Peripherally Acting Drugs
5.1.2 Centrally Acting Drugs
5.2 By Drug Type
5.2.1 Prescription Drugs
5.2.2 OTC Drugs
5.3 By Geography
5.3.1 North America
22.214.171.124 United States (By Mechanism of Action and By Drug Type)
126.96.36.199 Canada (By Mechanism of Action and By Drug Type)
188.8.131.52 Mexico (By Mechanism of Action and By Drug Type)
184.108.40.206 United Kingdom (By Mechanism of Action and By Drug Type)
220.127.116.11 Germany (By Mechanism of Action and By Drug Type)
18.104.22.168 France (By Mechanism of Action and By Drug Type)
22.214.171.124 Italy (By Mechanism of Action and By Drug Type)
126.96.36.199 Spain (By Mechanism of Action and By Drug Type)
188.8.131.52 Rest of Europe (By Mechanism of Action and By Drug Type)
184.108.40.206 China (By Mechanism of Action and By Drug Type)
220.127.116.11 Japan (By Mechanism of Action and By Drug Type)
18.104.22.168 India (By Mechanism of Action and By Drug Type)
22.214.171.124 Australia (By Mechanism of Action and By Drug Type)
126.96.36.199 South Korea (By Mechanism of Action and By Drug Type)
188.8.131.52 Rest of Asia-Pacific (By Mechanism of Action and By Drug Type)
5.3.4 Middle East and Africa
184.108.40.206 GCC (By Mechanism of Action and By Drug Type)
220.127.116.11 South Africa (By Mechanism of Action and By Drug Type)
18.104.22.168 Rest of Middle East and Africa (By Mechanism of Action and By Drug Type)
5.3.5 South America
22.214.171.124 Brazil (By Mechanism of Action and By Drug Type)
126.96.36.199 Argentina (By Mechanism of Action and By Drug Type)
188.8.131.52 Rest of South America (By Mechanism of Action and By Drug Type)
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Arena Pharmaceuticals, Inc.,
6.1.3 Bayer AG
6.1.4 Bristol-Myers Squibb
6.1.5 Currax Pharmaceuticals LLC
6.1.6 Eisai, Co. Ltd
6.1.7 F. Hoffmann-La Roche AG
6.1.8 GlaxoSmithKline PLC
6.1.9 Merck & Co. Inc.
6.1.10 Norgine B.V.
6.1.11 Novo Nordisk AS
7 MARKET OPPORTUNITIES AND FUTURE TRENDS